Introduction
Endothelial cells line blood vessels as a quiescent barrier maintaining the homeostasis of tissues and organs in the body. When new vessels are required to vascularize hypoxic tissues, heal wounds, or nourish tumors, endothelial cells undergo changes in cell phenotype, including increased migration, proliferation, and tubulogenesis, collectively termed angiogenesis (Carmeliet and Jain, 2000) . The molecular regulation of the angiogenic phenotype requires coordinated input from a number of signaling molecules. One potential important regulator of the angiogenic response is the small molecular weight GTPase Ras, which is proximally positioned upstream of a number of important signal transduction networks (Ehrhardt et al., 2002) .
Recently, we reported that Ras activation is required for the proangiogenic response to vascular endothelial cell growth factor (VEGF), including proliferation, migration, and branching morphogenesis (Meadows et al., 2001) . Several lines of evidence implicate Ras in developmental angiogenesis. Mice deficient in either p120-rasGAP or NF-1, proteins that facilitate Ras inactivation, fail to form organized vascular networks (Henkemeyer et al., 1995; Gitler et al., 2003) . Similarly, deletion of Sos1, a positive regulator of Ras activation, leads to cardiovascular and yolk sack defects, and embryonic lethality (Wang et al., 1997) . Lastly, disruption of the Ras effector, B-Raf, results in vascular defects in mice and mid-gestational death (Wojnowski et al., 1997) .
Activating Ras mutations have also been linked to the formation of endothelial-derived tumors, including liver angiosarcomas and cardiac hemangiosarcomas induced by chemical carcinogens (Marion et al., 1991; Hong et al., 2000) . In addition, immortalized endothelial cells expressing oncogenic Ras converted to an angiogenic phenotype and formed angiosarcomas in mice (Arbiser et al., 1997) . However, it is unclear from these studies if activation of Ras in endothelial cells was sufficient to mediate this phenotype switch, or if it required immortalization. In addition, the tumor growth and angiogenic conversion may have been the result of changes in the paracrine expression of VEGF induced by Ras (Arbiser et al., 1997) , and ultimately the generation of a number of Ras-independent signals, as is well documented in tumors of several origins (Rak et al., 2000a, b) . Therefore, we sought to determine if Ras activation is sufficient to induce the initiation of the angiogenic phenotype in primary endothelial cells.
Using adenovirus delivery of a Ras V12 mutant to primary endothelial cells, we found that Ras activation is sufficient to drive branching morphogenesis, cell migration, membrane ruffling, and cell cycle progres-sion. An increase in Akt, Erk, and Jnk signaling accompanied these changes. The signaling requirements for the angiogenic change in phenotype bifurcated; proliferation required ERK, while migration was influenced by both ERK and PI3K. Taken together, these results suggest that Ras is capable of driving an angiogenic switch in the phenotype of primary endothelial cells, in the absence of immortalization or angiogenic factors.
Results
To introduce activated Ras into primary endothelial cells, we generated an adenovirus carrying an active HA-tagged Ras V12 mutant, coexpressing a GFP marker. Primary endothelial cells were infected with adenoviruses at an MOI of 5-10. Under these conditions, we observed no cellular toxicity. Western blotting confirmed expression of the HA-tagged Ras V12 mutant. Ad.GFP and Ad.Ras V12 infected cells to similar levels as demonstrated by levels of GFP expression ( Figure 1a ) and as verified by fluorescence microscopy (data not shown).
Next, we evaluated the activation of Erk, PI3K, and SAPK/Jnk in endothelial cells expressing Ras V12 . Growth factors often stimulate these signals in a Rasdependent manner (Minden et al., 1994; Klinghoffer et al., 1996; Matsumoto et al., 1999; Meadows et al., 2001) , and these signals are known to regulate cell responses critical for angiogenesis including motility, growth, and survival (Fox et al., 1996; Thakker et al., 1999; Yu and Sato, 1999; Meadows et al., 2001 ).
Western blotting with phosphospecific antibodies to Erk, Jnk, and Akt, a kinase activated downstream of PI3K, demonstrated that all these signals were elevated in response to activated Ras (Figure 1b-d) .
In the presence of angiogenic factors, endothelial cells elongate, scatter, and form branching networks in threedimensional cultures (Montesano et al., 1983) . We previously demonstrated that branching morphogenesis, in response to VEGF, is Ras dependent (Meadows et al., 2001 ). In our current study, we sought to determine whether Ras activation alone would be sufficient to drive this response. We found that cells expressing Ras V12 formed branching networks on collagen gels in the absence of added angiogenic factors; in contrast, cells expressing GFP formed monolayer structures with only occasional sprouts (Figure 2 ). Branching morphogenesis is a complex phenotype mediated by a combination of growth factor signaling, matrix interactions, and physical forces. We sought to define further the effects of Ras activation on individual endothelial cell phenotypes altered in response to angiogenic stimuli, that is, cell migration and proliferation.
The migration of endothelial cells is a major component of the angiogenic response (Carmeliet, 2000) , and several reports link Ras signaling to cell (Sosnowski et al., 1993; Fox et al., 1994; Suzuki et al., 2000; Meadows et al., 2001) . We investigated whether Ras activation is sufficient to drive endothelial cell motility. Ad.Ras V12 induced prominent membrane ruffles and loss of stress fibers in human umbilical vein endothelial cells (HUVECS) cultured on glass coverslips coated with collagen, while Ad.GFP-infected cells maintained a mix of circumferential and transcellular actin fibrils, with no distinct lamellapodia ( Figure 3a) . As the induction of membrane ruffles is a morphological phenotype characteristic of motile cells (Ridley et al., 1992) , we measured the effect of Ras V12 expression on endothelial migration. Ad.Ras V12 promotes a 2.5-fold increase in cell migration in the absence of angiogenic stimuli (Figure 3b ), a response equivalent to the VEGFinduced cell migration in control GFP cells. Interestingly, VEGF further enhanced the Ras V12 migratory response, suggesting that VEGF may regulate the migration response through a distinct pathway. Endothelial cell proliferation is also required for new blood vessel growth (Takeshita et al., 1995; Carmeliet, 2000) . Our previous studies demonstrated that Ras activity was essential for VEGF-induced DNA synthesis (Meadows et al., 2001) . Therefore, we were interested in the effect of activated Ras V12 on cell cycle progression in primary endothelial cells. Oncogenic Ras exerts either positive or negative effects on growth, depending on the cellular context. Active Ras induces proliferation and cellular transformation in immortalized cells (Land et al., 1983; Newbold and Overell, 1983; Yoakum et al., 1985) and some primary cell types (Gire et al., 1999) . In contrast, several primary cell types exhibit cycle arrest (Serrano et al., 1997; Woods et al., 1997; Goi et al., 1999) . We found that the expression of Ras V12 resulted in an increase in DNA synthesis, as measured by [ 3 H]thymidine incorporation ( Figure 4a ). Similar results were found when we performed this experiment using BrdU incorporation; an assay normalized for cell number, demonstrating that this effect was not due to survival differences (not shown). VEGF did not further augment the Ras V12 response. Western blotting showed an increase in Cyclin D1 expression in cells infected with Ad.Ras V12 (Figure 4b ), consistent with increased proliferation (Weber et al., 1997; Gille and Downward, 1999) . In contrast, no substantial increases in p21 CIP/WAF or p27 kip were detected (Figure 4b ), proteins often associated with Ras/Raf-mediated cell cycle arrest Pumiglia and Decker, 1997; Sewing et al., 1997; Woods et al., 1997) .
Levels of ERK and PI3K activity are enhanced in response to activated Ras ( Figure 1 ). These effector pathways have been linked to cell proliferation and motility in some cases, but not in others (Klemke et al., 1997; Reiske et al., 1999; Meadows et al., 2001; Goncharova et al., 2002) . We sought to determine if Erk and PI3K were signaling intermediates in Ras V12 -induced proliferation and migration in endothelial cells, utilizing the well-characterized pharmacological inhibitors LY294002 (inhibits PI3K activity) and U0126 (inhibits Erk activation). The effectiveness of these agents was documented under conditions identical to those described for the migration and proliferation assays. We show that LY294002 (10 mm) completely inhibited the phosphorylation of Akt (a PI3K-dependent response) induced by Ras V12 (Figure 5a ). Similarly, Ras V12 -mediated Erk phosphorylation was inhibited by incubation with 1 mm U0126 (Figure 5a ).
We used UO126 and LY294002 to investigate the role of the Erk and PI3K signals in mediating the Rasinduced proliferation response. While inhibiting PI3K caused no change in cell proliferation, inhibiting Erk activation reduced DNA synthesis mediated by Ras V12 to levels observed in serum-starved cells expressing GFP alone ( Figure 5b ). As the basal levels of DNA synthesis were suppressed following inhibition of ERK, there appears to be an inductive response to Ras that is Erk independent. However, the induction seen under these conditions only achieves levels seen under quiescent conditions.
Cell migration was stimulated in Ad.Ras V12 -infected cells despite the presence of the inhibitors LY294002 and U0126; however, each compound produced a partial inhibition of the migratory response (Figure 5c ). These data suggest that the two pathways may be acting in a cooperative or parallel manner to regulate migration. In order to follow up on this possibility, we added both inhibitors simultaneously, resulting in complete inhibition of the Ras V12 -induced migration response (Figure 5d ). Ras V12 stimulates Jnk activation and this coupled with the demonstrated effects of Jnk-kinase in mediating the effects of VEGF (Pedram et al., 1998) led us to investigate the role of Jnk in Ras V12 -induced cell cycle progression and migration. We utilized a kinase dead, Flag-tagged dominant-negative Jnk mutant to inhibit Jnk signal transduction (Li et al., 1996; Dan et al., 2002) . Western blot analysis with antibodies to the Flag and HA tags confirmed the expression of our mutant proteins (Figure 6a ). We found that Jnk mediates both cell proliferation and migration stimulated by activated Ras. Endothelial cells coinfected with dominant-negative Jnk mutant and Ras V12 showed a reduction in S phase entry when compared to cells infected with Ras V12 alone (Figure 6b ). In addition, dominantnegative Jnk inhibited the number of migrating cells stimulated by Ras V12 (Figure 6c ). The release of angiogenic factors into the local environment is a mechanism that tumors use to recruit new blood vessels to facilitate its growth (Lazar-Molnar et al., 2000) . Mutant Ras proteins increase VEGF production in immortalized epithelial cells and fibroblasts transfected with oncogenic Ras (Rak et al., 2000a) . Therefore, we reasoned that the Ras V12 phenotype we observed might be the result of an autocrine secretion of VEGF stimulated by Ras. To address this question, we measured VEGF levels in the cell lysates and conditioned media of Ad.Ras V12 -infected cells. As positive controls, we also analysed cells infected with Ad.VEGF or Ad.GFP and stimulated with and without VEGF (50 ng/ml). We were able to detect by Western analysis VEGF levels as low as 1 ng/ml (Figure 7a) , which is well below the ED 50 for VEGF (Conn et al., 1990) . Western blotting demonstrated that cells infected with Ad.VEGF and Ad.GFP-infected cells treated with VEGF contained readily detectable levels of VEGF present in their conditioned media; however, no VEGF was detected in the conditioned media of Ad.Ras V12 -infected cells. We also measured whole-cell lysates, in the event that cell-secreted VEGF was strongly associated with the extracellular matrix. While cells infected with Ad.VEGF ectopically expressing VEGF contained large amounts of VEGF in whole-cell lysates, cells infected with Ad.GFP alone or Ad.Ras V12 contained no detectable levels of VEGF. These data suggest that Ras V12 does not induce an upregulation in VEGF in primary endothelial cells (Figure 7b) , and that the Ras V12 is directly inducing the angiogenic change in cell phenotype. To confirm these observations, we measured VEGF levels using an ELISA. VEGF concentrations from the conditioned media of cells infected with GFP and Ras V12 were comparable, yielding 11.170.32 and 10.770.40 pg/ml, respectively. In contrast, VEGF was detected at a concentration of 2015.7773.7 pg/ml in conditioned media taken from a VEGF-secreting human renal cell carcinoma cell line, 786-O.
Discussion
Our data indicate that Ras activation in primary endothelial cells is sufficient to enhance several cellular phenotypes that contribute to the angiogenic response including, branching morphogenesis, cell migration, and . Importantly, we found no evidence of secretion of VEGF production in Ras
V12
-expressing endothelial cells, as has been described in other cell systems, ruling this out as a mechanism driving the Ras V12 phenotype. This may result from the presence of normal p53 in our primary cultures, as previous investigations have demonstrated a strong repressive effect of p53 on oncogene-induced VEGF transcription (Mukhopadhyay et al., 1995; Zhang et al., 2000; Pal et al., 2001) .
Ras activation is required for motility in several systems including growth factor-induced chemotaxis in myoblasts (Suzuki et al., 2000) , and bFGF-mediated wound closure in endothelial cells (Sosnowski et al., 1993; Fox et al., 1994) . In addition, we demonstrated previously a requirement for Ras activation in VEGFinduced endothelial cell migration (Meadows et al., 2001) . Our current findings show that Ras V12 is sufficient to induce a motile phenotype in primary endothelial cells. The induction of membrane ruffling by Ras V12 is consistent with the promigratory phenotype generated by activated Ras in fibroblasts through a Rac-dependent mechanism (Ridley et al., 1992) . Several papers have recently demonstrated the importance of Rac in endothelial cell motility (Soga et al., 2001; Ghosh et al., 2002; Zeng et al., 2002) . Several lines of evidence suggest that Rac activation is a likely contributor to the motile phenotype induced by Ras: (1) we observe strong activation of the Rac effector Jnk; (2) dominantnegative Jnk inhibits the Ras V12 -induced migratory response, and (3) a dominant-negative Rac N17 inhibits membrane ruffling and migration in response to Ras V12 (Meadows et al., 2003 unpublished data) .
Interestingly, VEGF stimulation further enhances the Ras V12 response, suggesting that there may be several parallel pathways controlling endothelial cell migration. Consistent with our hypothesis that Ras may be inducing the activation of Rac, a recent report demonstrates that activated Rac and VEGF produce additive effects on migration (Soga et al., 2001) . One possibility for the additive effect of VEGF may come from work demonstrating a role for p38 in VEGFinduced cell migration in endothelial cells (Rousseau et al., 1997) ; we found that p38 is not activated by Ras (data not shown).
The expression of Ras V12 in immortalized cells correlates with transformation; however, expression in primary cells results in various outcomes with respect to proliferation. It promotes cell cycle arrest in some primary cell types (Serrano et al., 1997; Zhu et al., 1998) , but stimulates cell proliferation in others (Lemoine et al., 1990; Gire et al., 1999) . We found increased DNA synthesis following the expression of Ras V12 . Consistent with this, cyclin D1 levels were elevated in Ras
-infected endothelial cells, while p21
CIP and p27 KIP levels remained largely unaffected. In contrast to the migration response to Ras V12 , the proliferation response seemed to show identical signaling requirements to those previously reported for VEGF (Pedram et al., 1998; Meadows et al., 2001; Zeng et al., 2001) . Interestingly, while Ras V12 expression does not induce acute cell cycle arrest, studies in our laboratory, investigating the role of Raf activation, demonstrate that activation of Raf in primary endothelial cells results in the induction of p21 CIP and premature senescence (McMullen et al., 2003 unpublished data) . The long-term effects of expressing oncogenic Ras in primary endothelial cells are unclear. Adaptive changes might take place beyond the window of the experiments conducted in this study, including loss of a proliferation response. This possibility is currently under investigation.
Interestingly, while the current studies were underway, two recent reports reported that oncogenic Ras promotes cell cycle arrest in primary endothelial cells mediated by p21 CIP . We cannot be certain as to the differences in these reported results. In the studies by Suzuki et al. (2002) , Ras V12 induced cell cycle arrest in contact-inhibited endothelial cells. In contrast, our studies utilized subconfluent cells. Given the dynamic signal modulation capabilities of the adherens junctions (Conacci-Sorrell et al., 2002) , and the necessity of cells to maintain contact inhibition, an exciting possibility is that signals mediated by cadherin engagement may control the balance between pro-and antiproliferative signals mediated by Ras. Indeed, it has previously been demonstrated that engagement of VE-Cadherin results in the inhibition of endothelial cell proliferation (Caveda et al., 1996) . In the other report, Ras L61 induced cell cycle arrest only at higher viral titers; p21 CIP was not induced at lower viral titers, comparable to those used in our study (Spyridopoulos et al., 2002) . Previous investigators have demonstrated that differential effects on cell proliferation can be achieved by variations in the 'strength of the signal', that is, lower levels of Raf activation result in cell proliferation, while higher levels of Raf activation induce cell cycle arrest (Woods et al., 1997) .
Taken together, these data begin to define the complex inter-relationship between Ras activation, Ras effectors, and the manifestation of the angiogenic phenotype. In our studies, activated Ras promotes endothelial cell migration, proliferation, as well as branching morphogenesis; these are all requisite steps in new vessel formation. These data suggest that Ras activation may be sufficient to induce many of the requisite phenotypes for angiogenesis and coupled with our previous data, define Ras as a potential target for antiangiogenic therapies. Our observations also hint at an intriguing possibility: the acquisition of activating Ras mutations, through carcinogen exposure or inheritance, may create an angiogenically predisposed population of endothelial cells. Increased proliferation rates of these cells could be predisposing for the acquisition of additional mutations and eventually impact the development of vascular tumors and/or anomalies in vascular structure. Congruent with this hypothesis, Ras mutations have been documented in tumors of endothelial cell origin that arise following carcinogen exposure (Marion et al., 1991; Hong et al., 2000) , and introducing immortalized endothelial cells expressing active Ras into mice resulted in the development of lesions resembling angiosarcoma (Arbiser et al., 1997; MacKenzie et al., 2002) . Similarly, a line of mice generated in the process of creating a tetracycline-regulated Ras allele developed spontaneous hemangioma (Fisher et al., 2001) . In the absence of secondary mutations and progression to vascular tumors, it is possible that Ras mutations will create a hyper-responsive angiogenic environment and thereby function as an important accelerant for the progression of cancer and other diseases dependent upon angiogenesis.
Materials and methods

Generation of recombinant adenovirus
An H-Ras V12 cDNA obtained from Channing Der (University of North Carolina, Chapel Hill, NC, USA) was PCR amplified with an N-terminal hemagluttinin tag (HA) (Meadows et al., 2001) . The HA-tagged Ras V12 was subcloned into the pAdTrack-CMV and the AdEasy system was used to generate recombinant adenoviruses (He et al., 1998; Meadows et al., 2001) . Viruses were titered as previously described (O'Carroll et al., 2000) , and used at a multiplicity of infection (MOI) of 5. This results in moderate expression in nearly 100% of cells (not shown) as monitored by fluorescence microscopy (not shown). The GFP adenovirus was from Q-Biogene (Carlsbad, CA, USA).
Cell culture
HUVECS from pooled donors were purchased from VEC Technologies (Troy, NY, USA). Cells were cultured on tissue culture dishes coated with 0.2% gelatin at 371C and 5% CO 2 in the presence of M199 media supplemented with 20% FBS, 1% penicillin/streptomycin, 10 mg/ml heparin, and 50 mg/ml of endothelial cell growth supplement (Collaborative Biomedical Products). Bovine lung microvessel endothelial cells (BLMVECS) were purchased from VEC Technologies (Troy, NY, USA) and were cultured in MCDB-131 medium supplemented with 20% FBS, 10 mm l-glutamine, and 1% penicillin/streptomycin on tissue culture dishes coated with 0.2% gelatin. Experiments were conducted in the presence of serum-free MCDB media supplement with or without VEGF or in MCDB containing 2.5% FBS and VEGF as indicated.
Western blotting
Western Blot analysis was conducted using the following antibodies: phospho-ERK, ERK2, p21, p27, and VEGF (Santa Cruz, Santa Cruz, CA, USA), HA (BabCo, Richmond, CA, USA), cyclin D1 (NeoMarkers, Freemont, CA, USA), phospho-Akt, Akt, phospho-Jnk, and Jnk (New England Biolabs, Beverly, MA, USA). Confluent HUVECS were infected with adenoviruses overnight in serum-free MCDB. Cells were stimulated with 50 ng/ml VEGF (R&D, Minneapolis, MN, USA) for 15 min. For phospho-Erk analysis, cells were stimulated with VEGF for 5 min, as it elicits the maximal VEGF-induced Erk activation (Meadows et al., 2001) . In some studies, cells were pretreated for 30 min with 10 mm LY294002 or 1 mm U0126, specific pharmacological inhibitors of PI3K and MEK, respectively. Western blotting conditions were as previously described (Meadows et al., 2001) .
Branching morphogenesis assay
Collagen gels were prepared using a neutral solution of 1 mg/ ml collagen in 1 Â DMEM, supplemented with 50 ng/ml VEGF as indicated. Following polymerization, BLMVECS infected with Ad.GFP or Ad.Ras V12 were seeded at 1 Â 10 5 per 12 well and were grown in MCDB supplemented with 2.5% FBS and 1% penicillin/streptomycin for 48 h. Cells were fixed with 3.7% formaldehyde and photographed with a Spot-2 Digital Camera as previously described (Lee et al., 1999; Meadows et al., 2001) .
Cellular migration
Transwell migration assays were performed essentially as described previously (Meadows et al., 2001) . Infected HU-VECS were trypsinized and 5 Â 10 4 cells were seeded onto the upper well of 8 m tissue culture inserts precoated with 10 mg/ml collagen. The lower chamber contained 50 ng/ml VEGF or vehicle and the cells were allowed to migrate for 4 h. Cells were fixed in 3.7% formaldehyde/PBS and quantified (Meadows et al., 2001) .
Labeling of actin cytoskeleton
HUVECS infected with Ad.GFP or Ad.HA-Ras V12 were trypsinized and 5 Â 10 4 cells were seeded onto 12 mm circle glass coverslips coated with 10 mg/ml collagen. After 4 h, in order to mimic the migration assay, cells were fixed with 3.7% formaldehyde, permeabilized with 0.1% Triton X-100/PBS for 30 min and stained for filamentous actin with 0.5 U/ml of Texas Red-X Phalloidin (Molecular Probes) as previously described (Meadows et al., 2001 ).
Measurement of DNA synthesis
HUVECS were seeded at 1.2 Â 10 4 cells per 24 well in the presence of complete M199 media and allowed to adhere overnight. Cells were infected with Ad.GFP or Ad.HA-Ras V12 for 16 h in serum-free MCDB-131, and stimulated with or without 25 ng/ml VEGF for an additional 16 h. In some experiments, cells were preincubated with inhibitors LY294002 or U0126 for 16 h prior to the addition of VEGF. S-phase nuclei were labeled by incubating cells with 0.1 mCi of [ 
VEGF detection
Proteins from cell supernatants of HUVECS infected with Ad.GFP, Ad.Ras V12 , Ad.VEGF, and Ad.GFP stimulated with 50 ng/ml VEGF were precipitated with TCA. The supernatants were spiked with 500 ng of GST-Erk to control for equal recovery and 10 mg of BSA to serve as a protein carrier. Proteins were pelleted and washed several times with cold acetone. Pellets resuspended in Laemmli sample buffer were sonicated and analysed by Western blotting.
VEGF concentrations of conditioned media from cells infected with Ad.GFP and Ad.Ras V12 for 24-h were determined by ELISA using a Quantikine human VEGF kit (R&D, Minneapolis, MN, USA). A VEGF secreting human renal cell carcinoma cell line 786-0 was used as a positive control. A VEGF standard curve ranging from 15 to 1000 pg/ml was used to calculate VEGF concentrations.
